net dbt
biopharma sale give visibl
leverag unlock valu ev/ebitda
biopharma sale give visibl leverag unlock valu
ge announc sale biopharma busi life scienc portion
healthcar segment total consider
cash remaind transfer pension liabil after-tax proce
expect rang deal expect close sale
ge retain remain imag diagnost equip contrast imag
life scienc busi gener sale mid-teen margin
view divestitur posit unlock life scienc valu provid
visibl balanc sheet note sum-of-the-part sotp analysi
alreadi assign healthi multipl healthcar franchis base
life scienc multipl transact well-receiv rate agenc
given better visibl cash inject stabl portfolio
top manag retent healthcar post biopharma sale key risk
multipl sale lower end expect
potenti sale life scienc previous discuss press
assign like acquisit price tag asset assum
multipl highlight acquir portion life
scienc busi revenu total life scienc sale
divestitur translat ev/sal multipl ev/ebitda multipl
came lower end estim rang proce line
public trade life scienc peer posit side divestitur provid clear
visibl balanc sheet path de-lever
like close end portfolio ration
think divestitur biopharma busi ge like close
portfolio ration think stock start trade close
ep fundament go forward ge expect host outlook call
march also underscor manag like better visibl
core oper balanc sheet compani also expect file
week host insur teach-in call march provid visibl
assumpt long-term insur busi insid ge capit like
indic lower near-term risk addit capit requir rais po
roll valuat
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
ge highli diversifi global industri
compani busi organ broadli
seven segment power renew energi
healthcar transport ge capit
compani product servic includ power
locomot medic equip compressor
other half busi tie servic
aftermarket support
believ ge signific cost cut
opportun new leadership note
compani undergon signific
reinvest cycl posit well
competit standpoint howev see
stock outperform face possibl
neg earn revis
po assum ge capit
po base appli ev/ebitda multipl
industri estim assign neg valu ge
capit ev/ebitda would put compani discount vs compar
view appropri given compani mix execut elev leverag
tabl ge valuat analysi compar
gener electr po
note estim calendar decemb year end
margin busi ge capit neg
po base appli ev/ebitda multipl industri
estim assign neg valu ge capit ev/ebitda would
put compani discount vs compar view appropri given
compani mix execut elev leverag
downsid risk po on-going end market pressur growth margin
power execut issu outsid power larger-than-expect capit
requir ge capit
andrew obin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
